Adult Psychiatry· 27 min read
Psychedelics for Mental Health: What the 2026 Evidence Actually Shows
Published: April 2026 | Updated: July 2026 | By: Dr. Baghel | Category: Adult Psychiatry
On April 18, 2026, President Trump signed a psychedelic therapy executive order directing federal agencies to accelerate research and access to psychedelic drugs for mental health conditions. The order allocates $50 million through ARPA-H to match state investments in psychedelic research, directs the FDA to expedite review of psychedelics already designated as Breakthrough Therapies, and establishes a Right to Try pathway for investigational compounds including ibogaine. Psilocybin and ibogaine remain Schedule I controlled substances under federal law, which means nothing is legally prescribable as of this writing.
The picture has moved twice since then. In January 2025 the FDA approved esketamine as a standalone treatment for treatment-resistant depression, the first drug in this broad category cleared to be used on its own. And on July 14, 2026, the FDA finalized its guidance for how psychedelic clinical trials should be run and announced a public hearing for September 14, 2026 on how supervised psychedelic treatment might eventually work. Neither action approves psilocybin or MDMA, and neither changes what a psychiatrist can prescribe today. Both tell you the federal pathway is being built in earnest, which is a real change from a year ago.
The announcement has generated significant media attention and substantial patient interest. Patients are already contacting psychiatric practices asking when these treatments will be available, whether the order changes access now, and whether they should wait for psychedelic therapy rather than pursue conventional treatment. These are reasonable questions that deserve serious clinical answers.
This article addresses what the executive order actually does, what the research actually shows, what the safety concerns are, and what patients in North Carolina should understand about the current clinical landscape. For patients seeking evaluation for treatment-resistant conditions, the companion article on treatment-resistant depression provides a framework for thinking about options that are available now.
What the Executive Order Actually Does
The executive order directs four concrete actions. First, the FDA Commissioner is instructed to provide Commissioner’s National Priority Vouchers to psychedelic drugs with existing Breakthrough Therapy designation, which expedites agency review. Second, the FDA and DEA are directed to establish a pathway for eligible patients to access investigational psychedelic drugs under the Right to Try Act, with specific mention of ibogaine compounds. Third, HHS is required to allocate $50 million through the Advanced Research Projects for Health program to match state-level psychedelic research investments. Fourth, HHS, FDA, and the Department of Veterans Affairs are directed to increase clinical trial participation.
What the executive order does not do is equally important. It does not reschedule psilocybin, ibogaine, MDMA, or LSD. It does not approve any psychedelic compound for medical use. It does not make these substances legally prescribable by a psychiatrist in North Carolina or any other state. An executive order is not FDA approval, and FDA approval is what permits a compound to be prescribed as a medical treatment.
The practical effect is acceleration of a pipeline that was already moving. Psilocybin has held FDA Breakthrough Therapy designation for treatment-resistant depression since 2018 and for major depressive disorder since 2019. MDMA-assisted therapy for PTSD was submitted to the FDA for approval in 2023, received a complete response letter in August 2024, and remains under review. The executive order may shorten timelines for these pending decisions but does not substitute for them.
What Changed in July 2026: The Final Guidance and the September Hearing
The executive order was the political signal. The July 2026 guidance is the operational one. On July 14, the FDA published the final version of its guidance Psychedelic Drugs: Considerations for Clinical Investigations, upgrading a 2023 draft into finished agency thinking on how these trials should be designed, dosed, and monitored.
The single biggest problem in psychedelic research is functional unblinding: patients almost always know whether they got the drug or the placebo, which inflates the apparent benefit. That problem is a large part of why the FDA rejected MDMA in 2024. The final guidance is the agency’s attempt to tell sponsors how to run trials it can actually trust, and it names the exact issues a careful clinician worries about, including screening for psychosis and suicidality, cardiac risk, informed consent, and the potential for diversion.
Alongside the guidance, the FDA opened a public hearing set for September 14, 2026 on the future therapeutic use of psychedelics. The listed topics read like a preview of how supervised treatment would actually be delivered: provider training and credentialing, patient safety and screening, informed consent, diversion control, and access, including telehealth screening and follow-up. The comment docket is open through October 5, 2026.
The informed-consent rules behind all of this date to the 1970s, after the CIA spent 20 years dosing people who never agreed to it. I cover that record in MKUltra and informed consent.
Patients keep missing one thing. The notice explicitly excludes scheduling and legalization from its scope. A hearing about how future treatment might work does not make anything legal, and finalized trial guidance is not an approval. Psilocybin, MDMA, LSD, and ibogaine all remain Schedule I. Nothing about July changed what your psychiatrist can prescribe.
The Regulatory Timeline at a Glance
- 2018 to 2019: Psilocybin receives FDA Breakthrough Therapy designation for treatment-resistant depression, then for major depressive disorder.
- 2023: MDMA-assisted therapy for PTSD is submitted to the FDA for approval.
- August 2024: The FDA rejects the MDMA application in a complete response letter and asks for another trial.
- January 2025: Esketamine is approved as a standalone (monotherapy) treatment for treatment-resistant depression.
- June 2025 and February 2026: Two phase 3 psilocybin trials report positive topline results for treatment-resistant depression.
- April 18, 2026: The executive order directs agencies to speed research and access.
- July 14, 2026: The FDA finalizes its psychedelic trial guidance.
- September 14, 2026: The FDA holds a public hearing on future therapeutic use.
What the Research Actually Shows
The clinical evidence for psychedelic-assisted therapy varies substantially by compound and condition. Some compounds have robust randomized controlled trial data. Others have only open-label studies or anecdotal reports. The findings below represent the strongest published data rather than the full landscape, organized by compound.
The Compounds Side by Side
| Compound | Federal schedule | Strongest evidence to date | FDA status | Legal US medical access now |
|---|---|---|---|---|
| Psilocybin | Schedule I | Phase 3 in treatment-resistant depression (positive topline, modest effect) | Breakthrough Therapy; rolling application underway | None (clinical trials; state programs in OR and CO) |
| MDMA | Schedule I | Two phase 3 trials in PTSD | Rejected August 2024; not resubmitted | None (clinical trials) |
| LSD (MM120) | Schedule I | Phase 2b in generalized anxiety disorder | Breakthrough Therapy; phase 3 underway | None (clinical trials) |
| Ibogaine | Schedule I | Open-label studies only; serious cardiac risk | Early federal research; no application | None (some patients travel abroad) |
| Ketamine and esketamine | Schedule III (ketamine) | Multiple randomized trials in treatment-resistant depression | Esketamine approved, including as monotherapy (2025); racemic ketamine used off-label | Yes, through psychiatric and infusion settings |
Psilocybin
Psilocybin is the active compound in “magic mushrooms” and has the strongest clinical evidence base among the classical psychedelics. The trial that put it on the map, published in the New England Journal of Medicine in 2022, showed that a single 25 mg dose beat a 1 mg control by about 6.6 points on the MADRS depression scale at three weeks in treatment-resistant patients (1). Earlier open-label data from Imperial College London showed response rates near 50% at five weeks (2), and a 2023 phase 2 trial in JAMA reported benefit in major depressive disorder as well (7).
The trials measure whether psilocybin works. For why it might, from the 5-HT2A receptor to the neuroplasticity data, see how psilocybin works in the brain.
For where psilocybin came from, from teonanácatl to Albert Hofmann’s 1958 isolation to its placement in Schedule I, see the history of psilocybin.
Psilocybin has since crossed into phase 3, and the phase 3 numbers are more sobering than the early ones. COMPASS Pathways has reported positive topline results from two large trials: COMP005 (258 patients, single 25 mg dose, reported June 2025) and COMP006 (581 patients, reported February 2026, with durability data out to six months). Both hit their primary endpoint. But the effect in COMP005 was modest, a placebo-subtracted difference of roughly 3.6 MADRS points, about half of what the 2022 trial suggested, and “response” was scored on a lenient 25% improvement threshold. These are company-reported topline numbers, not yet peer-reviewed, so the full data deserve a careful read when they publish.
The company has said it is submitting a rolling application to the FDA, with a possible launch in the first half of 2027 if the agency approves and the DEA reschedules the drug. That timeline is real, and it still depends on two federal decisions that haven’t happened. Psilocybin holds Breakthrough Therapy designation for treatment-resistant depression (since 2018) and major depressive disorder (since 2019). Oregon and Colorado allow supervised psilocybin sessions under state law, though it remains Schedule I federally. The Johns Hopkins Center for Psychedelic and Consciousness Research has led much of the modern work.
Psilocybin has been tested well beyond depression. Two randomized, double-blind trials in 2016 gave a single dose to patients facing life-threatening cancer, and in the larger one about 80% still showed clinically significant drops in depression and anxiety six months later. The second, smaller trial found much the same. A 2022 double-blind trial in alcohol use disorder put heavy drinking days at under 10% in the psilocybin group, versus about 24% on an active placebo. And a small 2026 trial randomized smokers to psilocybin or the nicotine patch. About 40% of the psilocybin group stayed abstinent at six months, compared to 10% on the patch.
Early pilots hint at a signal in OCD and anorexia, though the work there is thin. None of these uses is FDA-approved, and none are available as standard care.
LSD (Lysergic Acid Diethylamide)
LSD research has accelerated significantly in the past two years. A landmark phase 2b trial published in JAMA in 2025 evaluated MM120, a pharmaceutical formulation of LSD, in 198 adults with moderate-to-severe generalized anxiety disorder (3). A single 100 microgram dose produced rapid and dose-dependent reduction in anxiety symptoms, with effects lasting at least twelve weeks after a single treatment. Notably, the study showed efficacy without concurrent psychotherapy, which differs from most psychedelic protocols that require intensive therapeutic integration.
A 2022 phase 2 study published in Biological Psychiatry demonstrated that LSD reduced anxiety symptoms in patients with life-threatening illness, with effects persisting sixteen weeks after treatment (4). Phase 3 trials for MM120 in generalized anxiety disorder are currently in progress. Although LSD has been studied longer than almost any other psychedelic, rigorous modern trials have only recently begun to establish its clinical profile.
MDMA
MDMA is technically classified as an entactogen rather than a classical psychedelic, meaning it promotes emotional openness and interpersonal connection rather than primarily producing hallucinogenic effects. The MAPP2 phase 3 trial published in Nature Medicine in 2023 randomized 104 participants with moderate-to-severe PTSD to MDMA-assisted therapy or placebo with therapy (5). The primary outcome, change in Clinician-Administered PTSD Scale score, showed a mean reduction of 23.7 points in the MDMA group compared to 14.8 points in the placebo group. Seventy-one percent of MDMA participants no longer met PTSD diagnostic criteria at study end, compared to 48% of placebo participants.
MDMA-assisted therapy was submitted to the FDA in 2023, and in August 2024 the agency rejected it in a complete response letter, citing concerns about trial design and the functional-unblinding problem described above. The company-led program stalled after that. The active research has shifted to trials supported by the Department of Veterans Affairs and other federal agencies, which is a notable change: the government is now helping run the studies it once only reviewed. MDMA remains Schedule I and is not approved for any use.
For how MDMA-assisted therapy works in the brain, and the full account of why two positive phase 3 trials still could not satisfy the FDA, see how MDMA-assisted therapy works.
MDMA, PTSD, and North Carolina’s Veterans
This part is close to home. Coastal North Carolina has one of the densest veteran and active-duty populations in the country, with Camp Lejeune, Cherry Point, and New River all within reach of Wilmington. When national headlines say “psychedelics for veterans,” those are the patients who call.
In July 2026, HHS and the VA signed a five-year agreement to prepare the VA health system for psychedelic therapies if and when the FDA approves them, covering workforce training, treatment protocols, and real-world data collection (see the HHS announcement). This is real institutional movement, and it is preparation for a future that hasn’t arrived yet. No psychedelic is approved or available through the VA today, and MDMA is still Schedule I.
For a veteran with PTSD right now, the guidance is the same as for any patient: the proven options are available today and worth optimizing first, including trauma-focused therapy with a trained therapist and, where indicated, medication. A clinical trial is the only supervised route to MDMA. As a forensic psychiatrist, I pay close attention to the screening and consent questions the FDA’s September hearing is built around, because PTSD frequently travels with the exact risk factors, including cardiac issues and prior psychosis, that make unscreened psychedelic use dangerous.
Ibogaine
Ibogaine is derived from the West African iboga plant and has been studied primarily for substance use disorders and, more recently, traumatic brain injury. A Stanford study published in Nature Medicine in 2024 evaluated magnesium-ibogaine therapy in 30 special operations veterans with traumatic brain injury and psychiatric sequelae (6). The protocol used magnesium coadministration specifically to mitigate ibogaine’s known cardiotoxicity. Results at one month showed 86% remission of PTSD, 83% remission of depression, and 83% remission of anxiety, with no serious cardiovascular adverse events.
These results are remarkable but come from a single open-label study without a placebo control. Ibogaine’s original clinical interest emerged from observations that a single dose appeared to interrupt opioid dependence, and it remains one of the most promising candidates for addiction treatment despite significant safety concerns discussed in detail below.
Federal interest has picked up since the executive order. In July 2026, NIDA revived and validated older ibogaine data and began funding work toward a formal FDA research application for opioid use disorder, part of the same federal push behind the VA agreement. That is a real step toward studying the drug properly. But there’s still no completed controlled trial showing ibogaine treats opioid use disorder, and the cardiac risk described below hasn’t gone away.
Ayahuasca and DMT
Ayahuasca is a traditional Amazonian brew containing dimethyltryptamine (DMT) combined with a monoamine oxidase inhibitor from a second plant. DMT alone is rapidly metabolized when taken orally, and the MAO inhibitor is what allows DMT to remain active long enough to produce psychedelic effects. A 2019 randomized trial in Psychological Medicine demonstrated rapid antidepressant effects of ayahuasca in treatment-resistant depression, with significant symptom reduction within 24 hours that persisted at seven days.
Intravenous and inhaled DMT are being studied as shorter-duration alternatives to ayahuasca, with experiences lasting 15 to 30 minutes rather than four to six hours. Compounds like SPL026 (from Small Pharma) and BPL-003 have advanced into phase 2 trials for treatment-resistant depression. The short duration makes these formulations potentially more practical for clinical integration than compounds requiring all-day sessions.
5-MeO-DMT
5-MeO-DMT is a distinct tryptamine found in the venom of the Sonoran Desert toad and synthesizable in laboratories. Its experience profile differs from classical psychedelics, producing more intense but shorter-duration effects lasting roughly 20 to 40 minutes. Early clinical trials are examining 5-MeO-DMT for treatment-resistant depression, with phase 2 data from BPL-003 and GH001 suggesting rapid symptom reduction after a single dose.
The compound has received increasing research attention because the short duration and high intensity may produce therapeutic benefit efficiently, and it lacks the extended time burden of psilocybin or MDMA protocols. Safety data in clinical populations remain limited, and this compound should not be pursued outside of research settings.
Mescaline and Peyote
Mescaline is the active compound in peyote and San Pedro cactus and has the longest documented history of use in indigenous ceremonial contexts. Modern clinical research on mescaline is limited compared to psilocybin and LSD, partly because of its long duration (eight to twelve hours) and partly because of its cultural and legal sensitivity. Peyote is protected for religious use by members of the Native American Church under federal law, but mescaline is otherwise Schedule I.
A 2022 observational study suggested potential benefits for depression and anxiety, but rigorous randomized trials do not yet exist. Mescaline is not a realistic near-term clinical option in the United States.
Ketamine and Esketamine
Ketamine is a dissociative anesthetic rather than a classical psychedelic, but it occupies similar clinical ground: rapid effects on depression and an altered state of consciousness. It is the one compound in this article with real evidence and legal medical access at the same time. Esketamine (Spravato), the S-enantiomer, was approved in 2019 for treatment-resistant depression, in 2020 for depression with acute suicidal ideation, and in January 2025 as a standalone treatment, meaning it no longer has to be paired with an oral antidepressant (8). Racemic ketamine is used off-label for depression, and a 2023 head-to-head trial in the New England Journal of Medicine found intravenous ketamine was non-inferior to electroconvulsive therapy for non-psychotic treatment-resistant depression (9).
Ketamine works through NMDA receptor antagonism rather than serotonin 2A agonism, and its effects appear to involve BDNF signaling and synaptic plasticity, the same neuroplasticity framework discussed in the companion article on chemical imbalance and depression. It carries real risks. Repeated use can bring bladder toxicity, dissociation, blood-pressure spikes, and genuine abuse potential, which is why it belongs in a monitored setting. Clinical access is through specialty infusion clinics, psychiatric offices offering ketamine treatment, and certified Spravato providers. I’m preparing to offer IV ketamine and Spravato at my Wilmington office.
Schedule a consultation if you want to discuss whether your treatment-resistant symptoms warrant a comprehensive re-evaluation of available options.
The Ibogaine Safety Problem
Ibogaine receives disproportionate attention in the executive order because of strong veteran advocacy and bipartisan political support. The clinical evidence is genuinely intriguing. The safety profile is genuinely concerning. Both facts need to be held simultaneously.
Ibogaine prolongs the QT interval on electrocardiogram, which can trigger life-threatening ventricular arrhythmias. At least thirty deaths have been reported in the medical literature in association with ibogaine use, predominantly from cardiac causes. The National Institutes of Health funded research on ibogaine in the 1990s but discontinued the work specifically due to cardiovascular toxicity concerns.
The Stanford MISTIC protocol addresses this directly through magnesium coadministration, which stabilizes cardiac conduction. This approach may prove to be the breakthrough that allows ibogaine to be used safely in clinical settings. It is also possible that broader clinical use will surface cardiac adverse events that did not appear in the small, carefully-selected Stanford cohort. The executive order accelerating Right to Try access means some patients will pursue ibogaine outside research settings, and the clinical infrastructure to manage cardiac complications does not yet exist in most of the country.
Patients traveling to Mexico for ibogaine treatment, a common current practice, face variable clinical standards, inconsistent cardiac monitoring, and no reliable framework for managing complications. This is a real risk, not a theoretical one.
One quieter safety point applies beyond ibogaine. Several of these compounds act on the serotonin 2B receptor, which, with repeated exposure, is the same mechanism behind the heart-valve damage seen with older weight-loss drugs. Single supervised doses in trials are a different risk profile than frequent microdosing at home, and the long-term cardiac safety of repeated use is not yet established (10).
What This Means for Access Right Now
The executive order does not provide any immediate legal pathway for a psychiatrist in North Carolina to prescribe psilocybin, ibogaine, MDMA, or LSD. These substances remain Schedule I. The order directs regulatory agencies to move faster, which is meaningful, but does not change the prescribing framework today.
Patients seeking legal access to psychedelic therapy currently have three options. First, enroll in clinical trials, which are recruiting at academic medical centers nationwide including several North Carolina sites. ClinicalTrials.gov maintains a searchable registry. Second, travel to Oregon or Colorado, the two states that have legalized psilocybin therapy with state-licensed facilitators. Third, pursue Right to Try access, which the executive order emphasizes but which requires navigating specific FDA pathways and typically applies only to terminal or severe conditions.
Ketamine is the exception to this landscape. It is FDA-approved for anesthesia and used off-label for treatment-resistant depression, and esketamine (Spravato) is FDA-approved for treatment-resistant depression, including as a standalone treatment since 2025. These are dissociative anesthetics rather than classical psychedelics, but they occupy similar clinical ground and are the nearest available option in the category. For patients whose depression hasn’t responded to conventional antidepressants, ketamine treatment is a legitimate option to explore with a qualified provider, without waiting for psilocybin or MDMA. Patients in North Carolina can read more in the article on depression treatment in North Carolina.
Psychedelic Therapy and Addiction
One of the most promising research areas for psychedelic-assisted therapy is substance use disorder. Psilocybin has the strongest controlled evidence of the psychedelics studied for it. Ibogaine’s original clinical interest emerged from observations that a single dose appeared to interrupt opioid dependence and reduce withdrawal symptoms. The mechanism is not fully understood but appears to involve resetting reward-pathway signaling and enabling psychological work that standard treatments cannot access.
Traditional addiction treatment in the United States remains dominated by medication-assisted treatment (methadone, buprenorphine, naltrexone), abstinence-based programs, and behavioral therapy. These are effective for many patients. For patients who have cycled through conventional treatments without sustained recovery, the interest in psychedelic alternatives is understandable and, given the emerging research, not unreasonable.
The honest clinical answer is that psychedelic-assisted addiction treatment is not yet available as standard care. Clinical trial enrollment remains the realistic path for patients interested in these approaches. Any patient pursuing ibogaine abroad should, at minimum, obtain a comprehensive cardiac workup, including ECG, echocardiogram when indicated, and assessment of QT interval, before traveling.
What Patients Should Not Do
Several patterns of patient behavior following this announcement are predictable and concerning.
Patients should not discontinue current psychiatric medications in anticipation of psychedelic therapy. SSRIs and SNRIs can blunt psychedelic effects, which has led some patients to stop antidepressants before seeking illegal psilocybin or ayahuasca experiences. Abrupt discontinuation causes withdrawal, potential rebound depression, and in some cases serious clinical deterioration. Medication tapering should always be clinician-supervised.
Patients should not pursue underground or unregulated psychedelic experiences based on the assumption that the executive order has legitimized them. Substances purchased outside regulated channels carry risks of contamination, incorrect identification, and unpredictable dosing. The legal status has not changed.
Patients should not travel internationally for ibogaine without comprehensive cardiac clearance and a clear plan for post-treatment follow-up. The deaths reported in the ibogaine literature overwhelmingly involve patients who had either unrecognized cardiac risk factors or inadequate monitoring.
Patients should not assume that psychedelic therapy will be available as standard clinical care within the next twelve months. The executive order accelerates a timeline measured in years, not weeks.
What Patients Should Consider Doing
For patients with treatment-resistant depression, PTSD, or addiction who are interested in psychedelic-assisted therapy, several steps are reasonable now.
First, ensure that conventional treatments have been optimized. “Treatment-resistant” should mean genuine failure of adequate trials at adequate doses, not incomplete response to a single medication. A comprehensive evaluation often identifies treatment options that have not been adequately tried. See the companion article on treatment-resistant depression for a detailed framework.
Second, consider ketamine or esketamine if indicated. These are legally available, evidence-based, and occupy similar clinical territory to emerging psychedelic therapies. For appropriate patients, they offer rapid symptom relief that may bridge the gap until psilocybin or MDMA receive approval.
Third, address underlying medical contributors. Depression and PTSD symptoms frequently overlap with hormonal imbalances, sleep disorders, and metabolic dysfunction. Testosterone evaluation in men, thyroid assessment, sleep apnea screening, and comprehensive labs are often more productive first steps than pursuing experimental treatments abroad. For patients whose sleep is disrupted, the companion article on the psychiatrist’s guide to sleep medications provides a detailed framework.
Fourth, monitor clinical trial availability. ClinicalTrials.gov lists active psychedelic trials, many of which actively recruit patients with treatment-resistant conditions. Enrollment provides supervised access to these therapies in a medically appropriate setting.
Schedule a consultation to discuss whether your situation warrants evaluation for any of these approaches.
The Broader Clinical Picture
The executive order reflects a genuine shift in federal attitudes toward psychedelic therapy and is likely to accelerate research and eventual access. It does not change what is clinically available today. The gap between what is becoming possible and what is currently legal is uncomfortable for patients who are suffering now, and the impulse to pursue what is available elsewhere is understandable.
The psychiatric community’s responsibility is to hold both truths at once. Psychedelic-assisted therapy represents a potentially significant advance for conditions where conventional treatments have failed. It also carries real risks that are amplified when treatment happens outside regulated clinical settings. Patients deserve honest clinical assessment of their specific situation rather than either blanket dismissal of psychedelics as dangerous or blanket enthusiasm for psychedelics as the answer.
For patients in North Carolina, the practical question is what to do with the next twelve months while the regulatory landscape evolves. The answer is typically not to wait. A comprehensive re-evaluation may bring meaningful relief now, without the risks of unregulated psychedelic use. It can point to changes in your current treatment or to evidence-based supplements. I’m also preparing to offer IV ketamine and Spravato at my Wilmington office, and the waitlist is open. For patients curious about how peptide-based approaches compare with conventional antidepressants, the article on peptides versus SSRIs provides a direct comparison.
Frequently Asked Questions
Did the FDA approve psychedelics in July 2026?
No. The FDA finalized guidance on how psychedelic clinical trials should be designed, and it scheduled a public hearing for September 14, 2026 on possible future therapeutic use. Both are steps in building a research and review pathway. Neither approves any psychedelic, and the hearing notice specifically excludes scheduling and legalization. Psilocybin, MDMA, LSD, and ibogaine remain Schedule I and cannot be prescribed.
What is the September 14, 2026 FDA hearing about?
It is a public hearing on how supervised psychedelic treatment might work if compounds are approved in the future. The listed topics include provider training and credentialing, patient screening and safety, informed consent, diversion control, and access, including telehealth screening and follow-up. It is a public listening and comment session, and it carries no power to legalize or reschedule anything. The public comment period runs through October 5, 2026.
Can veterans get psychedelic therapy through the VA?
Not yet. In July 2026, HHS and the VA signed a five-year agreement to prepare the VA system for psychedelic therapies if the FDA approves them, including training and protocols. This prepares the VA for a possible future. It changes nothing about access today: no psychedelic is approved or available through the VA, and MDMA, the compound studied most for PTSD, is still Schedule I. Veterans seeking supervised access would do so through a clinical trial.
Does Trump’s executive order mean I can now get psilocybin or ibogaine from a psychiatrist in North Carolina?
No. Psilocybin, ibogaine, MDMA, and LSD all remain Schedule I controlled substances under federal law. The executive order directs federal agencies to accelerate research and review of these compounds, but it does not change their legal status. FDA approval is what would permit a psychiatrist to prescribe these substances, and no psychedelic has yet received FDA approval for any indication.
How soon might psychedelic therapy actually be available as standard treatment?
The timeline is still uncertain, but it has sharpened. Psilocybin has the strongest data and has reported two positive phase 3 trials, with its maker submitting a rolling FDA application and pointing to a possible launch in the first half of 2027, contingent on FDA approval and DEA rescheduling. MDMA was rejected in 2024 and has no active approval timeline. A realistic expectation is that psilocybin could become available through supervised clinics in roughly the next two years if the remaining federal decisions go its way, with other compounds further behind.
Is ketamine the same as psychedelic therapy?
Ketamine is a dissociative anesthetic rather than a classical psychedelic like psilocybin or LSD. Its pharmacology differs significantly, though it produces altered states of consciousness and has rapid antidepressant effects. Ketamine is legally available in the United States for off-label treatment of depression, and esketamine (Spravato) is FDA-approved specifically for treatment-resistant depression. For patients seeking legal access to a treatment with similar rapid-acting antidepressant properties to psychedelics, ketamine is the nearest available option.
Is it safe to travel to Mexico for ibogaine treatment?
Ibogaine has caused at least thirty documented deaths, predominantly from cardiac arrhythmias. Clinical standards at ibogaine clinics in Mexico vary substantially. Patients who travel for treatment should obtain comprehensive cardiac evaluation beforehand, including electrocardiogram and assessment of QT interval. A clear plan for post-treatment follow-up and management of potential complications is essential. The Stanford protocol using magnesium coadministration appears to significantly reduce cardiac risk, but not all clinics follow this or equivalent protocols. This is a real risk that should not be minimized.
Should I stop my antidepressant to prepare for psychedelic therapy?
No. SSRIs and SNRIs may blunt psychedelic effects, but discontinuation should never be self-directed. Abrupt discontinuation causes withdrawal symptoms, potential rebound depression, and in some cases serious clinical deterioration. Psychedelic therapy is not legally available in North Carolina, so there is no immediate reason to taper. If you enroll in a clinical trial that requires medication washout, the protocol will specify supervised tapering. Any medication change should be made in consultation with your prescribing clinician.
What should I do if I have treatment-resistant depression or PTSD and am interested in psychedelic therapy?
The first step is confirming that your treatment has genuinely been optimized. Many patients labeled treatment-resistant have not actually received adequate trials of multiple medication classes at adequate doses. A comprehensive psychiatric re-evaluation often identifies conventional options that have not been fully tried. Consider ketamine or esketamine if indicated and available. Address underlying medical contributors such as hormonal imbalances, sleep disorders, and metabolic dysfunction. Monitor clinical trial availability through ClinicalTrials.gov. Pursue the full legally-available treatment landscape before considering experimental approaches abroad.
Get a Comprehensive Evaluation of Your Options
I offer comprehensive psychiatric evaluation for treatment-resistant symptoms. I see patients by video anywhere in North Carolina, and in person at my Wilmington office by request. Board-certified in general and forensic psychiatry (ABPN). Honest clinical discussion of what is available, what is emerging, and what makes sense for your specific situation.
Or call (910) 612-6015
This article is for educational purposes and does not constitute medical advice. Psilocybin, ibogaine, MDMA, and LSD are Schedule I controlled substances under federal law and are not legally prescribable in North Carolina. Baghel Psychiatry does not provide psychedelic-assisted therapy. Patients considering clinical trial enrollment or travel for psychedelic treatment should discuss their specific situation with a qualified prescribing clinician. Treatment decisions depend on individual clinical factors that can only be assessed through a comprehensive evaluation.
References
1. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637-1648. PMID: 36322843.
2. Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with Psychological Support for Treatment-Resistant Depression: Six-Month Follow-Up. Psychopharmacology (Berl). 2018;235(2):399-408. PMID: 29119217.
3. Robison R, Barrow R, Conant C, et al. Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial. JAMA. 2025;334(15):1358-1372. PMID: 40906494.
4. Holze F, Gasser P, Muller F, Dolder PC, Liechti ME. Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biol Psychiatry. 2023;93(3):215-223. PMID: 36266118.
5. Mitchell JM, Ot’alora G M, van der Kolk B, et al. MDMA-Assisted Therapy for Moderate to Severe PTSD: A Randomized, Placebo-Controlled Phase 3 Trial. Nat Med. 2023;29(10):2473-2480. PMID: 37709999.
6. Cherian KN, Keynan JN, Anker L, et al. Magnesium-Ibogaine Therapy in Veterans with Traumatic Brain Injuries. Nat Med. 2024;30(2):373-381. PMID: 38182784.
7. Raison CL, Sanacora G, Woolley J, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. 2023;330(9):843-853. PMID: 37651119.
8. Janik A, Qiu X, Lane R, et al. Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(9):877-887. PMID: 40601310.
9. Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023;388(25):2315-2325. PMID: 37224232.
10. McIntyre RS. Serotonin 5-HT2B Receptor Agonism and Valvular Heart Disease: Implications for the Development of Psilocybin and Related Agents. Expert Opin Drug Saf. 2023;22(10):881-883. PMID: 37581427.